EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

The effect of synbiotic adjunct therapy on clinical and paraclinical outcomes in hospitalized COVID‐19 patients: A randomized placebo‐controlled trial

Mahsa Vaezi, Sahar Ravanshad, Mina Akbari Rad, Hossein Zarrinfar, Mona Kabiri iD

Journal of Medical Virology · 2023-02 · 95 (2)

DOI: 10.1002/jmv.28463 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Medical Virology, online erschienen am 11.01.2023. Verfasst von Mahsa Vaezi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Hauptthemen laut MEDLINE: Synbiotics, COVID-19, Probiotics. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Mashhad University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic approaches with immune‐modulatory effects such as probiotics and prebiotics adjuvant therapy may be essential to combat against COVID‐19 pandemic. The present trial aimed to reveal the efficacy of synbiotic supplementation on clinical and paraclinical outcomes of hospitalized COVID‐19 patients. The current randomized placebo‐controlled trial enrolled 78 hospitalized patients with confirmed COVID‐19 infection. Participants were randomly allocated to intervention and control groups that received synbiotic or placebo capsules twice daily for 2 weeks, respectively. The synbiotic capsule contains multi‐strain probiotics such as Lactobacillus (L.) rhamnosus , L. helveticus , L. casei , Bifidobacterium (B.) lactis , L. acidophilus , B. breve , L. bulgaricus , B. longum, L. plantarum, B. bifidum, L. gasseri , and Streptococcus (S.) thermophilus (10 9 CFU), as well as fructooligosaccharides prebiotic agent. Besides COVID‐19 clinical features, levels of proinflammatory interleukin‐6 (IL‐6), C‐reactive protein (CRP), erythrocyte sedimentation rate (ESR), liver and renal function markers, as well as hematological parameters, were assessed during follow‐up. The serum level of IL‐6 was significantly decreased in the intervention group compared to the placebo after 2 weeks of intervention ( p = 0.002). A significant difference was found regarding the count of white blood cells (WBC) within the synbiotic group from pre to post‐treatment ( p = 0.004). The levels of ESR ( p = 0.935) and CRP ( p = 0.952) had a higher reduction trend in the synbiotic group relative to the placebo, with no significant between‐group differences. Other findings had no statistical differences between groups. Our results provide the support that synbiotic adjuvant therapy for 2 weeks can be effective to modulate inflammatory responses against COVID‐19 infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SynbioticsCOVID-19ProbioticsHumansInterleukin-6PandemicsC-Reactive ProteinDouble-Blind Method

Stichwörter der Autor:innen

COVID-19clinical featuresinflammatory and noninflammatory markersmulti-strain probioticsprebiotics

Substanzen

Interleukin-6C-Reactive Protein

Autor:innen und Institutionen

  • Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.

ORCID-Profile: Mona Kabiri

Förderung

  • Mashhad University of Medical Sciences

Zitieren

APA

Vaezi, M., Ravanshad, S., Akbari Rad, M., Zarrinfar, H., & Kabiri, M. (2023). The effect of synbiotic adjunct therapy on clinical and paraclinical outcomes in hospitalized COVID‐19 patients: A randomized placebo‐controlled trial. Journal of Medical Virology, 95(2). https://doi.org/10.1002/jmv.28463

Vancouver

Vaezi M, Ravanshad S, Akbari Rad M, Zarrinfar H, Kabiri M. The effect of synbiotic adjunct therapy on clinical and paraclinical outcomes in hospitalized COVID‐19 patients: A randomized placebo‐controlled trial. Journal of Medical Virology. 2023;95(2). doi:10.1002/jmv.28463

BibTeX
@article{Vaezi2023,
  author = {Vaezi, Mahsa and Ravanshad, Sahar and Akbari Rad, Mina and Zarrinfar, Hossein and Kabiri, Mona},
  title = {The effect of synbiotic adjunct therapy on clinical and paraclinical outcomes in hospitalized COVID‐19 patients: A randomized placebo‐controlled trial},
  journal = {Journal of Medical Virology},
  year = {2023},
  volume = {95},
  number = {2},
  doi = {10.1002/jmv.28463}
}
Kostenlos starten →